electroCore announced that it has received patent issue notifications from the United States Patent and Trademark Office, USPTO. The two patents were issued on April 2, 2024, and relate to electroCore’s non-invasive vagus nerve stimulation, nVNS, technology: US Patent No. 11,944,815 entitled “Non-Invasive Nerve Stimulation with Mobile Device” generally relates to a system for transcutaneously stimulating a nerve in a patient that includes a downloadable software application configured to wirelessly transmit a therapy regimen to a stimulator. US Patent No. 11,944,807 entitled “Vagal Nerve Stimulation for Treating Central Nervous System Disorders” generally relates to methods for treating central nervous disorders, such as PTSD, fibromyalgia, anxiety and TBI by applying electrical impulses to the vagus nerve according to a stimulation protocol that includes at least two doses each day.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECOR:
- electroCore Expands Intellectual Property Portfolio
- Electrocore’s Battle with Cyber Threats: Protecting Sensitive Data Amidst Rising Security Risks
- electroCore reports Q4 EPS (61c) vs. ($1.22) last year
- electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
- electroCore to Participate in Upcoming Investor Conferences